美女免费一级视频在线观看

Norstella debuted its NorstellaLinQ data platform on Tuesday, an offering from the pharmaceutical intelligence solutions provider that aggregates and cleans real-world data from various sources to provide high quality, comprehensive patient information.

Utilizing Norstella’s proprietary forecasting, clinical, regulatory, payer, coverage and commercial intelligence data, NorstellaLinQ connects data across different brands and data sets, allowing users to gain a holistic view of patients.

Users can interact with the service by purchasing data to use in their preferred format or using pre-combined data for specific use cases.

Notably, NorstellaLinQ establishes a throughline between the company’s various subsidiaries, utilizing capabilities from Citeline, Evaluate, MMIT, Panalgo and The Dedham Group. 

Norstella has accumulated companies over the past few years, uniting them under the brand name in 2022 following the $5 billion merger with Citeline. The firm also just bought J+D Forecasting, a U.K.-based pharma forecasting solutions company in January.

Ultimately, Norstella CEO Mike Gallup said the goal with NorstellaLinQ is to help find patients for both commercial and clinical trials, ensure that they are covered and can access necessary therapies.

He added that the platform launch wouldn’t have been possible without incorporating capabilities from innovative tools like generative AI and machine learning. He said the latter two technologies enable NorstellaLinQ to have data consistency, accuracy and the ability to quickly respond to new data challenges.

These are all timely answers to lingering questions pharma leaders had been pressing for in recent years, according to Gallup.

“In my opinion, we’re at a time in pharma that we as partners and suppliers can’t just throw things at [clients] and say, ‘Hey, go get a bunch of consultants and put it together on your own,’” he said. “It’s time for us to do what most other industries have done, which is provide real solutions and answers to their problems and not make them go pay millions of dollars to consultants to fix it.”

He underscored the agile nature of NorstellaLinQ, noting that a concern raised by a client about monitoring patient adherence to a medication was remedied within hours by the company’s data team. 

Specifically, they were able to combine a variety of datasets within NorstellaLinQ to provide an analysis of patient adherence and benchmark that adherence against the rest of the country.

Gallup used this example to illustrate the agility and responsiveness of the platform in a short period of time to provide contextual, application-driven data solutions.

Looking ahead, Norstella’s plans include continued expansion of linked datasets, flexible data models to adapt to various use cases and potential partnerships to integrate clients’ proprietary data.

As for how this offering fits into the larger narrative about how data is utilized by pharma companies, Gallup emphasized the importance of pushing boundaries and asking challenging questions, stressing that the service can now provide answers where previously it was impossible.